SLS is trading 6.2% down today at $14.49 as buyout speculation cools and traders take profits following a sharp multi-day rally to 52-week highs.
- The stock remains highly volatile ahead of pivotal Phase 3 REGAL trial results for its cancer vaccine candidate, galinpepimut-S.
- Today’s pullback largely reflects fading M&A chatter and profit-taking rather than any new fundamental setbacks or clinical data updates.